BLTE
Belite Bio, IncstockNASDAQADR
belite bio inc is a san diego based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. developed from our anti-rbp4 technology platform, our lead candidate, lbs-008, is currently in a phase i clinical trial for dry age-related macular degeneration and its juvenile form, stargardt disease. lbs-008 has received orphan drug status in the us and europe, as well as rare pediatric disease status in the us.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 155.94 | 2026-11-11 | -0.04% | 2.838 |
| 1M | 147.34 | 2026-10-19 | +5.80% | 1.086 |
| 3M | 162.57 | 2026-08-18 | -4.12% | 1.170 |
| 6M | 142.90 | 2026-05-18 | +9.08% | 1.002 |
| 1Y | 123.19 | 2025-11-18 | +26.54% | 1.093 |
| 2Y | 82.76 | 2024-11-18 | +88.35% | — |
| 5Y | 10.59 | 2022-04-29 | +1371.95% | 0.304 |
Belite Bio, Inc (NASDAQ:BLTE) stock price today is $155.88, and today's volume is 94,254. BLTE is down 1.167% today. The 30 day average volume is 175,262. BLTE market cap is $6.28B with 40.27M shares outstanding.